8-amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid | 148703-26-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 8-amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid
• 英文别名: 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid；8-Amino-7-chloro-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxylic acid；5-amino-6-chloro-2,3-dihydro-1,4-benzodioxine-8-carboxylic acid
• CAS: 148703-26-8
• 化学式: C₉H₈ClNO₄
• mdl: MFCD22041968
• 分子量: 229.62
• InChiKey: KGEWUGWPCVDMCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  81.8
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  8-amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid 在 氯化亚砜 、 一水合肼 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 9.25h， 生成 4-[5-(8-amino-7-chloro-2,3-dihydrobenzo[1,4]dioxan-5-yl)-[1,3,4]oxadiazol-2-yl]-[1,4']bipiperidinyl-1'-carboxylic acid ethyl ester
  参考文献：
  名称：

  HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS

  摘要：

  本发明涉及式(I)的新化合物，以及它们的药用盐和含有它们的组合物。 本发明还涉及制备上述新化合物的方法，以及它们的药用盐。式(I)的化合物在治疗与5-HT 4 受体相关的各种疾病中是有用的。

  公开号：

  US20140187581A1
• 作为产物：
  描述：

  8-氨基-2,3-二氢-苯并[1,4]二噁英-5-羧酸 在 N-氯代丁二酰亚胺 、 溶剂黄146 作用下， 反应 8.0h， 生成 8-amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid
  参考文献：
  名称：

  Pilot Scale Process Development of SL65.0102-10, an N-Diazabicyclo[2.2.2]-octylmethyl Benzamide

  摘要：

  The process development and improvements for route selection, adapted to large scale for the pilot-scale preparation of SL65.0102-10, an N-diazabicyclo[2.2.2]-octylmethyl benzamide, a 5-HT3 and 5-HT4 receptor active ligand for the treatment of neurological disorders such as cognition impairment, are described in this article. Notable steps and enhancements are compared to the original route, including the improvement of a chiral epoxide synthesis by shortening the number of chemical steps, the deprotection of a quaternary ammonium salt, and the redesign of the final amidification coupling to avoid chromatography.

  DOI：

  10.1021/acs.oprd.6b00262

文献信息

• Esters of 3-hydroxy-piperidinemethanol derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US06096761A1

  公开（公告）日：2000-08-01

  The present invention of compounds of formula (I), ##STR1## a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R.sup.1 is C.sub.1-6 alkyloxy, C.sub.2-6 alkenyloxy or C.sub.2-6 alkynyloxy; R.sup.2 is hydrogen or C.sub.1-6 alkyloxy, or when taken together R.sup.1 and R.sup.2 may form a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with C.sub.1-6 alkyl; R.sup.3 is hydrogen or halo; R.sup.4 is hydrogen or C.sub.1-6 alkyl; L is C.sub.3-6 cycloalkyl, C.sub.5-6 cycloalkanone, C.sub.2-6 alkenyl optionally substituted with aryl, or L is a radical of formula -Alk-R.sup.5 -, Alk-X--R.sup.6, -Alk-Y--C(.dbd.O)--R.sup.8, or -Alk-Y--C(.dbd.O)--NR.sup.10 R.sup.11 wherein each Alk is C.sub.1-12 alkanediyl; and R.sup.5 is hydrogen, cyano, C.sub.1-6 alkylsulfonylamino, C.sub.3-6 cycloalkyl, C.sub.5-6 cycloalkanone, aryl, di(aryl)methyl or a heterocyclic ringsystem; R.sup.6 is hydrogen, C.sub.1-6 alkyl, hydroxyC.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, aryl or heterocyclic ringsystem; X is O, S, SO.sub.2 or NR.sup.7 ; said R.sub.7 being hydrogen, C.sub.1-6 alkyl or aryl; R.sup.8 is hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, aryl, arylC.sub.1-6 alkyl, di(aryl)methyl, C.sub.1-6 alkyloxy or hydroxy; Y is NR.sup.9 or a direct bond; said R.sup.9 being hydrogen, C.sub.1-6 alkyl or aryl R.sup.10 and R.sup.11 each independently are hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, aryl or arylC.sub.1-6 alkyl, or R.sup.10 and R.sup.11 combined with the nitrogen atom bearing R.sup.10 and R.sup.11 may form a pyrrolidinyl or piperidinyl ring both being optionally substituted with C.sub.1-6 alkyl, amino or mono or di(C.sub.1-6 alkyl)amino, or said R.sup.10 and R.sup.11 combined with the nitrogen bearing R.sup.10 and R.sup.11 may form a piperazinyl or 4-morpholinyl radical both being optionally substituted with C.sub.1-6 alkyl. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.

  本发明涉及化合物的公式（I），其立体化学异构体，N-氧化物形式或其药学上可接受的酸盐，其中R.sup.1为C.sub.1-6烷氧基，C.sub.2-6烯氧基或C.sub.2-6炔基氧基；R.sup.2为氢或C.sub.1-6烷氧基，或当R.sup.1和R.sup.2结合在一起时，可以形成一个具有以下结构的二价基团，其中在所述的二价基团中，一个或两个氢原子可以被C.sub.1-6烷基取代；R.sup.3为氢或卤素；R.sup.4为氢或C.sub.1-6烷基；L为C.sub.3-6环烷基，C.sub.5-6环戊酮，C.sub.2-6烯基，可选地取代芳基，或L为以下结构的基团-Alk-R.sup.5-，Alk-X--R.sup.6，-Alk-Y--C(.dbd.O)--R.sup.8或-Alk-Y--C(.dbd.O)--NR.sup.10R.sup.11，其中每个Alk为C.sub.1-12烷二基；R.sup.5为氢，氰基，C.sub.1-6烷基磺酰氨基，C.sub.3-6环烷基，C.sub.5-6环戊酮，芳基，二(芳基)甲基或杂环戒系统；R.sup.6为氢，C.sub.1-6烷基，羟基C.sub.1-6烷基，C.sub.3-6环烷基，芳基或杂环戒系统；X为O，S，SO.sub.2或NR.sup.7；其中R.sub.7为氢，C.sub.1-6烷基或芳基；R.sup.8为氢，C.sub.1-6烷基，C.sub.3-6环烷基，芳基，芳基C.sub.1-6烷基，二(芳基)甲基，C.sub.1-6烷氧基或羟基；Y为NR.sup.9或直接键；其中R.sup.9为氢，C.sub.1-6烷基或芳基，R.sup.10和R.sup.11各自独立地为氢，C.sub.1-6烷基，C.sub.3-6环烷基，芳基或芳基C.sub.1-6烷基，或R.sup.10和R.sup.11与携带R.sup.10和R.sup.11的氮原子结合，可以形成一个取代有C.sub.1-6烷基，氨基或单或二(C.sub.1-6烷基)氨基的吡咯烷基或哌啶烷基环，或R.sup.10和R.sup.11与携带R.sup.10和R.sup.11的氮原子结合，可以形成一个取代有C.sub.1-6烷基的哌嗪基或4-吗啉基基团。公开了制备所述产品的方法，包括所述产品的配方以及它们作为药物的用途，特别是用于治疗与胃排空障碍相关的疾病。
• Substituted heteroaryl pyridopyrimidone derivatives
  申请人：Sanofi-Aventis

  公开号：EP1939187A1

  公开（公告）日：2008-07-02

  A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof : wherein: Y represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 perhalogenated alkyl group or an amino group; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring; R2 represents a 4-15 membered heterocyclic group , R3 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R4 and R5 represent, each independently, a hydrogen atom, a C1-6 alkyl group, optionally substituted by 1 to 4 substituents selected from a halogen atom, a phenyl group, a hydroxyl group or a C1-6 alkoxy group; R6 represents a hydrogen atom, a C1-6 alkyl group ; a cycloalkyl group, or a halogen atom; R7 represents a hydrogen atom or a C1-6 alkyl group; n represents 0 to 3; m represents 0 to 1; o represents 0 to 2; in the form of a free base or of an addition salt with an acid. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  公式（I）表示的嘧啶酮衍生物或其盐，溶剂化合物或水合物：其中：Y代表两个氢原子、硫原子、氧原子或C1-2烷基基团和一个氢原子；Z代表键、氧原子、氮原子、硫原子、一个亚甲基基团，可选地由C1-6烷基基团、羟基、C1-6烷氧基、C1-2全卤代烷基或氨基中选择的一种或两种基团取代的亚甲基基团；R1代表2、3或4-吡啶环或2、4或5-嘧啶环；R2代表4-15成员的杂环基团，R3代表氢原子、C1-6烷基基团或卤原子；R4和R5分别代表氢原子、C1-6烷基基团，可选地取代1至4个取代基，所选取代基来自卤原子、苯基、羟基或C1-6烷氧基；R6代表氢原子、C1-6烷基基团；环烷基基团或卤原子；R7代表氢原子或C1-6烷基基团；n表示0到3；m表示0到1；o表示0到2；以自由碱或与酸的加成盐的形式存在。该发明还涉及一种药物，包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，如阿尔茨海默病。
• HETEROARYLAMIDE PYRIMIDONE COMPOUNDS
  申请人：Lochead Alistair

  公开号：US20100087449A1

  公开（公告）日：2010-04-08

  The present invention discloses a series of pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: Wherein X, Z, R1, R2, R3, R4, R5, R6, R7, n and m are as defined herein. Also disclosed herein are the methods of preparation of compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.

  本发明揭示了一系列由公式(I)或其盐、溶剂或水合物表示的嘧啶酮衍生物：其中X、Z、R1、R2、R3、R4、R5、R6、R7、n和m如此定义。本发明还揭示了制备公式(I)化合物的方法、其中间体以及它们在治疗各种疾病条件中的用途。
• Heteroaryl compounds used as pharmaceuticals
  申请人：SmithKline Beecham plc

  公开号：US05620992A1

  公开（公告）日：1997-04-15

  A compound of formula (I) ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, X.sub.1, X.sub.2, x, Y and Z are as defined in the specification are useful in the treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and CNS disorders.

  式(I)的化合物##STR1##其中R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5、X.sub.1、X.sub.2、x、Y和Z如规范中定义的那样，可用于治疗或预防胃肠道疾病、心血管疾病和中枢神经系统疾病。
• [EN] HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS<br/>[FR] COMPOSÉS HÉTÉROARYLES CONVENANT COMME LIGANDS DU RÉCEPTEUR 5-HT4
  申请人：SUVEN LIFE SCIENCES LTD

  公开号：WO2013042135A8

  公开（公告）日：2013-08-15